

CITE NO. ME

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : Please See Extra Sheet.

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : Please See Extra Sheet.

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
CAS ONLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Chem. abstr., Vol. 116, No. 21, 25 May 1992 (Columbus, OH, USA), pages 741-742, column 2, the abstract No. 214456r, KUJUNDZIC, N. 'Synthesis of 8-methyl-1,2,3,4-tetrahydropyrido[3,4-d]pyrimidine-2,4-diones.' Croat. Chem. Acta. 1991, 64(4), 599-606 (Eng).	1-4
A	US 3,754,887 A (BRANTLEY) 28 August 1973, see entire document, especially column 1.	31-36
A	WHITE et al. Heterocyclic Ureas: Inhibitors of Acyl-CoA:Cholesterol O-Acyltransferase as Hypocholesterolemic Agents. J. Med. Chem. 25 October 1996, Vol. 39, No. 22, pages 4382-4395, especially pages 4387-4389.	1-4, 37-48, 55-60

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to underlain the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X*	document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
B earlier document published on or after the international filing date	*Y*	document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A*	document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means		
P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

11 MARCH 1999

Date of mailing of the international search report

02 APR 1999

 Name and mailing address of the ISA/US
 Commissioner of Patents and Trademarks
 Box PCT
 Washington, D.C. 20231
 Facsimile No. (703) 305-3230

Authorized officer

LAURA L. STOCKTON

Telephone No. (703) 308-1235

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 4,183,854 A (CROSSLEY) 15 January 1980, see entire document, especially column 1.	1-4
X	WO 96/25157 A1 (SMITHKLINE BEECHAM CORPORATION) 22 August 1996, see entire document, especially pages 16-17.	49-54, 61-65, 74, 76
X	WO 97/40028 A1 (VERTEX PHARMACEUTICALS INCORPORATED) 30 October 1997, see entire document, especially pages 11, 12, 16, 22 and 24, compound 85.	66-70, 77